Best Life Sciences Companies in Uppsala, Sweden
The 63 best Life Sciences companies in Uppsala, Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: OssDsign.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Uppsala
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OssDsign Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma | $20M | 12 mo ago | 50 | — | Apple iCloud MailMicrosoft 365core-js+3 | Top 10M | 89 patents Orthopedic bone repair biomaterials: bone-filling implants and calcium-deficient silicate phosphate cements | 1 launch |
| 2 | Q-linea Fully automated platforms for pathogen detection | $18M | 99 mo ago | 149 | — | WordPressMySQLPHP+23 | Top 5M | 130 patents Clinical microbiology diagnostic instruments and sample preparation/handling technologies. | 1 partnership |
| 3 | Oasmia Company developing new drug formulations based on its nanoparticle based excipient technology | $14M | 80 mo ago | 19 | — | — | — | — | — |
| 4 | Gradientech Developer of an ultra-rapid system for antibiotic susceptibility testing | $12M | 68 mo ago | 36 | — | WordPressMySQLPHP+23 | Top 10M | 28 patents Advanced adhesive polymer coatings and biotech cassette assembly technologies | — |
| 5 | Cavidi Provider of molecular diagnostic kits for diagnosis and monitoring of viral infections | $12M | 100 mo ago | 45 | — | Cart FunctionalityWooCommerceWordPress+37 | Top 50M | 14 patents Sensitive viral nucleic acid detection and antiviral susceptibility assay technologies. | 2 launchs |
| 6 | C-RAD Standalone oncology treatment clinic | $11M | 76 mo ago | 9 | Cecilia Leeuw CEO | WordPressMySQLPHP+29 | Top 5M | — | — |
| 7 | Navinci Diagnostics Developer of products for the detection and quantification of proteins | $8M | 47 mo ago | 29 | — | WordPress Block EditorwpBakeryCart Functionality+37 | Top 10M | 16 patents Nucleic acid amplification and detection platforms, including phi29 polymerase stabilization and padlock probes. | 1 job opening · 1 award |
| 8 | Rarity Bioscience Developer of assays for diagnostics of cancer | $8M | 24 mo ago | 9 | Per Matsson Co-chair & co-founder | WordPressMySQLPHP+12 | Top 50M | 14 patents Targeted nucleic acid detection assays using variant-specific probes and blocking agents | 2 awards |
| 9 | Akiram Therapeutics Developer of radiopharmaceuticals for cancer treatment | $7M | 41 mo ago | 8 | — | — | — | 9 patents Therapeutic antibodies and binding proteins targeting CD44v6 for cancer treatment | — |
| 10 | Strike Pharma Developer of immuno therapeutics to treat cancer | $6M | 52 mo ago | 10 | Marten Winge Chief Executive Officer | WordPressMySQLPHP+14 | Top 10M | 31 patents Bispecific antibody/peptide conjugates and fusion proteins delivered via lipid nanoparticle carriers | — |
| 11 | Beactica Develops small molecule drugs for oncology | $5M | 4 mo ago | 17 | — | Windows ServerMicrosoft ASP.NETIIS+5 | Top 50M | — | — |
| 12 | Isconova Vaccine Adjuvants for Infectious DIseases and Veterinary Markets | $5M | 215 mo ago | 21 | — | — | — | 58 patents Iscom-based adjuvant compositions for low-toxicity influenza vaccine formulations | — |
| 13 | Biovica Drug response monitoring assay | $4M | 54 mo ago | 13 | Anders Rylander CEO | WordPressMySQLPHP+17 | Top 50M | — | — |
| 14 | Ilya Pharma Biological drugs for treating wounds in skin and mucosa | $4M | 68 mo ago | 21 | Mia Phillipson Co-Founder | — | — | 25 patents Probiotic and microbiome-based therapies for gut disorders and wound healing | — |
| 15 | Bio-Works Provider of an of agarose based chromatography products for protein and biomolecule analysis | $4M | 42 mo ago | 4 | — | ShopifyBootstrapShop Pay+25 | Top 5M | — | 1 expansion |
| 16 | Klaria Developer of alginate film technology for transmucosal drug delivery | $2M | 59 mo ago | 6 | Fredrik Hubinette Co-Founder | — | — | — | — |
| 17 | Olink Provider of products and services for human protein biomarker research and development | $1M | 42 mo ago | 138 | — | Apple iCloud MailMicrosoft 365Node.js+21 | Top 5M | 82 patents Multiplexed protein biomarker detection using proximity extension and RCA amplification | 2 launchs |
| 18 | Nanexa Developing a nanoparticle based drug delivery system | $668K | 116 mo ago | 21 | David Westberg CEO | WordPressPleskMySQL+17 | Top 10M | 124 patents Pharmaceutical solid dosage forms using gas‑phase deposited inorganic‑coated nanoparticles | — |
| 19 | LigandTracer Developer of instruments and software for real-time studies of biological interactions | $610K | 89 mo ago | — | Jos Buijs CEO | Cart FunctionalityWooCommerceWordPress+25 | Top 10M | — | — |
| 20 | Immuneed Company offering immunotoxicology and immunophenotyping services during preclinical phase of biologics… | $506K | 117 mo ago | 26 | — | ReactGatsbyCloudflare+17 | Top 50M | — | 1 launch |
| 21 | Double Bond Pharmaceutical Provider of a pharmaceutical company developing innovative treatments for various diseases, including… | $112K | 79 mo ago | 10 | Igor Lokot CEO | — | — | 21 patents Patents concentrated in health & consumer products | — |
| 22 | Cavis Technologies Developer of pressure guide wire for the diagnosis of coronary artery disease | $111K | 76 mo ago | 7 | — | — | — | — | — |
Top 12 Life Sciences companies in Uppsala
#1
Series A · Uppsala, Uppsala County · founded 2006 · 17 employees$5.1Mraised▾
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
- Feb 2026Grant (prize money)$3M
- Dec 2019Grant (prize money)$326.3K
- Jun 2019Series A—
- Sep 2018Grant (prize money)$58K
#2
Public · Uppsala, Uppsala County · founded 2011 · 50 employees$19.7Mraised▾
Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma. Its implants incorporate a proprietary calcium phosphate-based material composition, reinforced by titanium, and CAD-based manufacturing and design. It uses 3D printing technologies to produce implants using materials like titanium combined with cured ceramic tiles. Its products have applications in the reconstruction of facial bone after trauma, tumor resection or growth retardation due to irradiation, and the repair of hereditary facial defects such as paranasal augmentation in cleft patients and correction of hemifacial microsomia.
- Jun 2025Post IPO$16.5M
- Sep 2023Post IPO$13.6M
- Feb 2019Series A$6.9M
- Sep 2017Grant (prize money)—
#3
Series A · Uppsala, Uppsala County · founded 2021 · 9 employees$7.5Mraised▾
Developer of assays for diagnostics of cancer. It offers molecular amplification technology to detect DNA sequence variants that are used to track cancer mutations in patients' tissue or liquid biopsies.
- Jun 2024Series A$7M
- Feb 2023Seed$539.6K
- Nov 2022Seed—
#4
Series A · Uppsala, Uppsala County · founded 2022 · 8 employees$6.5Mraised▾
Developer of radiopharmaceuticals for cancer treatment. It offers a radiolabeled antibody for the treatment of Anaplastic thyroid cancer which binds to an epitope located on a membrane-bound protein called CD44v6.
- Jan 2023Series A$6.5M
#5
Series A · Uppsala, Uppsala County · founded 2009 · 36 employees$12.3Mraised▾
Developer of an ultra-rapid system for antibiotic susceptibility testing. The company uses microfluidics technology with live cell imaging for the study of cell responses in a linear concentration gradient. The company's products include QuickMIC that is used for testing antibiotic susceptibility, CellDirector, a microfluidic assay used for the generation of stable concentration gradients in cell culture, and Tracking Tool, used for automated analysis of cell migration.
- Oct 2020Series A$9M
- Mar 2020Grant (prize money)$634K
- Sep 2018Grant (prize money)$58K
- Sep 2018Seed$2.2M
#6
Series A · Uppsala, Uppsala County · founded 2004 · 29 employees$8.5Mraised▾
Developer of products for the detection and quantification of proteins. It offers in situ proximity ligation assay products based on proprietary unfolding proximity probes technology. It combines antibody-based proteomic technologies with fluorescence readout to create immunostaining where sensitivity and specificity meet in one assay, enabling high-quality protein detection and analysis in cells and tissues. It also offers an in-house immunostaining service.
- Jul 2022Series A$8.5M
#7
Public · Uppsala, Uppsala County · founded 1999 · 19 employees$14.3Mraised▾
Oasmia Pharmaceutical is engaged in the development of novel anti-cancer formulations based on well-established cytostatics targeted at human and animal health. The firm's lead candidate Apealea (Paclical) is a novel formulation of Paclitaxel, based on its patented excipient platform XR-17. The company has submitted a Marketing Authorization Application to the EMA in Feb 2016. XR-17 is the company's proprietary nano-sized excipient based on Vitamin A, which is a surfactant with micelle-forming capabilities. XR-17 can form micelles with water soluble compounds also and hence it can enclose several molecules in micelles regardless of their water solubility. This would thus reduce the no. of doses, as two drug substances can be infused in one go and thus their nanoparticle-based drug delivery technology has the capability to reduce side-effects and cater to multiple therapy areas. The company has 4 other drugs in the pipeline for cancers in humans and 2 drugs for animal cancers. Oasmia has capabilities for GMP manufacture of its drugs for clinical sales and trials. The company is also developing excipients based on semi-synthetic derivatives of retinoids and polyunsaturated fatty acid
- Oct 2019Conventional Debt$4.6M
- Sep 2018Post IPO$3.9M
- Apr 2018Post IPO$3.1M
- Nov 2017Post IPO$3.3M
#8
Series A · Uppsala, Uppsala County · founded 2006 · 4 employees$3.9Mraised▾
Bio-Works has a portfolio of products for the separation of proteins and other biomolecules. The companies agarose-based beads work beads are available in different sizes and for uses at the analytical research level as well as for separation on a large industrial scale. They also offer agarose beads for His-tag purification by affinity chromatography, affinity resins for immobilization of biomolecules, gel filtration chromatography, and other agarose-based purification solutions.
- Dec 2022Grant (prize money)$24.1K
- Jun 2016Series A—
- May 2016Grant (prize money)$181.9K
- Dec 2014Series A$3.9M
#9
Public · Uppsala, Uppsala County · founded 2008 · 149 employees$18.3Mraised▾
Q-linea develops fully automated platforms for pathogen detection. It uses a combination of circle-to-circle DNA amplification and proprietary 'padlock' probes for sensitive detection of bacteria and probes. The company claims that its technology can be heavily multiplexed, and allows up to 20000-plex measurements. Its flagship product ASTrID can use whole blood samples to perform both molecular pathogen detection and phenotypic antibiotic susceptibility in four and six hours respectively. First application is diagnosis of sepsis. In addition, Q-linea also has the AQUILA line of analyzers for the detection of biological warfare agents like anthrax.
- Mar 2018Series B$18.3M
#10
Seed · Uppsala, Uppsala County · founded 2020 · 10 employees$6Mraised▾
Developer of immunotherapeutics to treat cancer. The company is focusing on the development of immunotherapy solutions for the treatment of solid tumors by using proprietary ADAC technology which is known as Immune Gas Pedal (IMMGAP) technology.
- Feb 2022Seed$4.8M
- Jun 2021Seed$1.2M
#11
Public · Uppsala, Uppsala County · founded 2009 · 13 employees$4.3Mraised▾
Biovica develops assays for monitoring drug response. Its flagship assay DiviTum measures tumor response to therapies using an ELISA test. The assay uses bromodeoxyuridine (BrdU) as a thymidine substitute. The company uses the assay to provide services to biopharma companies in order to predict therapeutic efficacy of cancer drugs in clinical trials. It is currently awaiting approval for clinical use.
- Nov 2021Grant (prize money)$769.8K
- Jun 2016Series A$3.5M
- Sep 2015Grant (prize money)$770.8K
- Jun 2015Seed$761.2K
#12
Public · Uppsala, Uppsala County · founded 2004 · 9 employees$11.1Mraised▾
Standalone oncology treatment clinic
- Feb 2020Post IPO$11.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Uppsala researches in biotechnology
- Uppsala University33
- Uppsala University Hospital3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.